Iparomlimab
HCC - Hepatocellular Carcinoma
Hebei Medical University Fourth HospitalPhase 4 / ApprovedActive
BBB
74/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 70/ 100
- Competitive Position
- 81/ 100
Competitive context
21 Active assets in the HCC - Hepatocellular Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Apixaban Mansoura University | Phase 4 | BB |
WARFARIN Mansoura University | Phase 4 | B |
Enoxaparin Mansoura University | Phase 4 | B |
cc-5013 Shunda Du | Phase 2 | B |
OBI 3424 Zhejiang Hisun Pharmaceutical Co. Ltd. | Phase 2 | B |
View all 21 →
Same molecule, other indications
Iparomlimab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →